J&J's oral IL-23 blocker icotrokinra posts strong 2-year psoriasis data, adding to immunology pipeline

What happened

Johnson & Johnson released new two-year Phase 3 data for ICOTYDE (icotrokinra), an oral IL-23 receptor blocker, showing nearly three-quarters of plaque psoriasis patients achieved clear or almost clear skin with a continued favorable safety profile. The drug is positioned as the first targeted oral peptide for this indication, offering a potential convenience advantage over injectable biologics like J&J's own STELARA and TREMFYA. However, the press release provides no commercial launch timeline or market access details, and the drug must compete in an increasingly crowded psoriasis market with entrenched injectables and emerging oral options. This data bolsters J&J's immunology pipeline but does not address the company's primary near-term challenges: accelerated STELARA biosimilar erosion and unresolved talc litigation. While positive, the news is incremental and unlikely to materially shift the investment thesis at this stage.

Implication

For investors, this news adds another potential growth driver to J&J's immunology portfolio, which is crucial as STELARA continues to lose share to biosimilars. However, the drug is still in Phase 3 and likely years from commercialization, so it offers no immediate offset to the revenue erosion expected over the next 6-18 months. The oral administration could differentiate icotrokinra from injectable competitors, but adoption will depend on pricing, payer coverage, and real-world efficacy versus established treatments like Otezla (oral) and biologics like TREMFYA. The data does not change the company's valuation profile, which remains dominated by the STELARA decline trajectory and talc liability uncertainty. Thus, while the readout is encouraging, we maintain our WAIT stance and would only consider upgrading if immunology stabilization becomes evident in Q2-Q3 FY2026 results.

Thesis delta

The thesis remains largely unchanged: JNJ is a defensive but overvalued large-cap pharma facing discrete near-term headwinds. This icotrokinra data adds modest credence to the long-term immunology franchise, but does not offset the immediacy of STELARA biosimilar erosion or talc litigation risks. We see no reason to alter our WAIT rating or valuation scenarios based solely on this press release.